How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

851 results for

Antithyroid Drug

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease (PubMed)

Periodic Granulocyte Count Measuring Is Useful for Detecting Asymptomatic Agranulocytosis in Antithyroid Drug-Treated Patients with Graves' Disease Finding agranulocytosis (AG) at an early stage is important to improve outcome, but periodic granulocyte count monitoring is not generally recommended for patients with Graves' disease, because AG develops suddenly.At the Kuma Hospital, Graves' patients under antithyroid drug (ATD) treatment in an outpatient clinic have a granulocyte count

Full Text available with Trip Pro

2016 European thyroid journal

42. Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling. (PubMed)

' disease and Hashimoto's thyroiditis.Sixty-six patients (58 females:8 males) comprising 53 with Graves' disease and 13 with Hashimoto's thyroiditis were diagnosed at median 10.4 (2.9-15.8) years and followed up for 11.8 (2.6-30.2) years. Antithyroid drug (ATD) therapy was stopped electively in 35 patients after 4.5 (1.5-8.6) years, resulting in remission in 10/13 Hashimoto's thyroiditis and 10/22 Graves' disease. Side effects occurred in 12 patients receiving carbimazole, six of whom changed (...) Long-term outcome of thyrotoxicosis in childhood and adolescence in the west of Scotland: the case for long-term antithyroid treatment and the importance of initial counselling. Thyrotoxicosis is both rarer and more severe in children than in adults, rendering management difficult and often unsatisfactory.To ascertain outcome in a geographically defined area of Scotland between 1989 and 2014.Retrospective case note review with follow-up questionnaire to family doctors for patients with Graves

Full Text available with Trip Pro

2017 Archives of Disease in Childhood

43. Genetic variants associated with antithyroid drug-induced agranulocytosis

Genetic variants associated with antithyroid drug-induced agranulocytosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect (...) subgroup analyses will be performed. If one or more subgroup analyses cannot be performed due to insufficient data, the p-value will be adjusted accordingly. ">Other Subgroup analysis or meta-regression are used to explore between-study heterogeneity and can provide insight into the relationship between study characteristics (e.g. species, sex or drug class or dose) and effect size. They should be considered hypothesis-generating. Ideally, a threshold describing the number of studies per subgroup

2018 PROSPERO

44. AntiNeutrophil Cytoplasmic Antibody (ANCA)-positive small-vessel vasculitis associated with antithyroid drug therapy: How significant is the clinical problem? (PubMed)

AntiNeutrophil Cytoplasmic Antibody (ANCA)-positive small-vessel vasculitis associated with antithyroid drug therapy: How significant is the clinical problem? The aim of this review was to delineate the characteristics of antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis associated with antithyroid drugs (ATD). A PubMed search was made for English language articles using the search terms antithyroid drugs AND ANCA OR ANCA-associated vasculitis.The literature includes

2015 Thyroid

45. Better adherence to antithyroid drug is associated with decreased risk of stroke in hyperthyroidism patients. (PubMed)

Better adherence to antithyroid drug is associated with decreased risk of stroke in hyperthyroidism patients. An increased risk for ischaemic stroke has been reported in young hyperthyroidism patients independent of atrial fibrillation (AF). However, whether the use of antithyroid drugs in hyperthyroidism patients can reduce the occurrence of ischaemic stroke remains unclear.A total of 36,510 newly diagnosed hyperthyroidism patients during 2003-2006 were identified from the Taiwan National (...) Health Insurance Research database. Each patient was individually tracked for 5 years from their index date (beginning the antithyroid drugs) to identify those who suffered from new episode of ischaemic stroke. Medication possession ratio (MPR) was used to represent the antithyroid drug compliance. The association between the MPR and the risk of stroke was examined.The stroke incidence rates for hyperthyroidism patients with age < 45 years and age ≥ 45 years were 0.42 and 3.76 per 1000 person-years

2015 International journal of clinical practice

46. Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea (PubMed)

Characteristics of Korean Patients with Antithyroid Drug-Induced Agranulocytosis: A Multicenter Study in Korea Antithyroid drugs (ATDs) can lead to the development of agranulocytosis, which is the most serious adverse effect. Characteristics of ATD-induced agranulocytosis (AIA) have seldom been reported due to the rarity. In this study, we characterized the clinical features for AIA in Korean patients.We retrospectively reviewed data from patients with AIA diagnosed between 1997 and 2014

Full Text available with Trip Pro

2015 Endocrinology and Metabolism

47. Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases. Erratum (PubMed)

Mode of binding of the antithyroid drug propylthiouracil to mammalian haem peroxidases. Erratum The results in the article by Singh et al. [(2015), Acta Cryst. F71, 304-310] have been brought into question and the article is retracted.

Full Text available with Trip Pro

2015 Acta crystallographica. Section F, Structural biology communications

48. Congenital Anomalies in Children Exposed to Antithyroid Drugs In-Utero: A Meta-Analysis of Cohort Studies. (PubMed)

Congenital Anomalies in Children Exposed to Antithyroid Drugs In-Utero: A Meta-Analysis of Cohort Studies. Hyperthyroidism affects about 0.2%-2.7% of all pregnancies, and is commonly managed with antithyroid drugs (ATDs). However, previous studies about the effects of ATDs on congenital anomalies are controversial. Therefore, the present meta-analysis was performed to explore the risk of congenital anomalies in children exposed to ATDs in-utero.Embase, Pubmed, Web of Knowledge, and BIOSIS

Full Text available with Trip Pro

2015 PloS one

49. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. (PubMed)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.A prospective randomized clinical trial with long-term follow-up was conducted to evaluate (...) the effects of a second course of ATD therapy.A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod

2015 European Journal of Endocrinology Controlled trial quality: uncertain

50. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. (PubMed)

A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. There are scarce reports regarding the prognosis of a second course of antithyroid drug (ATD) therapy on recurrent Graves' disease (GD). The aim of this study was to assess the long-term remission rate after a second ATD therapy and verify significant clinical predictors of a remission.A prospective randomized clinical trial with long-term follow-up was conducted to evaluate (...) the effects of a second course of ATD therapy.A total of 128 recurrent GD patients who had finished a first regular ATD therapy were enrolled in this study, and prescribed methimazole (MMI) treatment with titration regimen. The patients were randomly assigned to two groups when the drug doses were reduced to 2.5 mg daily (qd). Group 1 was discontinued with 2.5 mg qd after about 5 months. Group 2 was continuously reduced to 2.5 mg every other day (qod) after 5 months and then discontinued with 2.5 mg qod

Full Text available with Trip Pro

2015 European journal of endocrinology / European Federation of Endocrine Societies Controlled trial quality: uncertain

51. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? (PubMed)

Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Antithyroid drugs (ATDs) may have teratogenic effects when used in early pregnancy.To review the association between the time period of ATD exposure in early pregnancy and the development of birth defects.We identified publications on birth defects after early pregnancy exposure to the ATDs methimazole (MMI; and its prodrug carbimazole (CMZ

Full Text available with Trip Pro

2014 European Journal of Endocrinology

52. Antithyroid Drugs and Congenital Heart Defects: Ventricular Septal Defect (VSD) is part of the Methimazole/Carbimazole Embryopathy. (PubMed)

Antithyroid Drugs and Congenital Heart Defects: Ventricular Septal Defect (VSD) is part of the Methimazole/Carbimazole Embryopathy. 25069457 2015 01 07 2018 12 02 1479-683X 171 5 2014 Nov European journal of endocrinology Eur. J. Endocrinol. Antithyroid drugs and congenital heart defects: ventricular septal defect is part of the methimazole/carbimazole embryopathy. C1-3 10.1530/EJE-14-0524 Andersen Stine Linding SL Department of EndocrinologyAalborg University Hospital, Sdr. Skovvej 15, 9000

Full Text available with Trip Pro

2014 European Journal of Endocrinology

53. Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis (PubMed)

Patient Knowledge of Antithyroid Drug-Induced Agranulocytosis Agranulocytosis is a serious side effect of antithyroid drugs.To ascertain the knowledge of patients and review the quality of information available on the internet.A questionnaire survey was performed for patients receiving antithyroid drugs. Patients attending endocrine clinics who were receiving antithyroid drug treatment (group A, n = 33) were interviewed. A further national cohort of patients (group B, n = 100) treated (...) with antithyroid drugs, participated in an online survey.60.9% of responders were not aware of the common symptoms of agranulocytosis. 18.6% had never received any information about side effects. Of the 108 patients who recalled receiving information, 30% rated the quality as 'poor' or 'not good at all'. Structured interviews of group A patients revealed that almost half (45.5%, 15/33) had experienced symptoms that could be indicative of agranulocytosis, but only 53.3% (8/15) had a blood count checked

Full Text available with Trip Pro

2014 European thyroid journal

54. Antithyroid Arthritis Syndrome: A Case Report and Review of the Literature (PubMed)

Antithyroid Arthritis Syndrome: A Case Report and Review of the Literature We herein report the case of a 38-year-old Japanese woman with antithyroid arthritis syndrome who experienced severe migratory polyarthritis after the initiation of thiamazole therapy. The patient's symptoms promptly disappeared without any sequelae after the withdrawal of the drug. Antithyroid arthritis syndrome is poorly characterized, and the findings from our literature review indicate that this syndrome exhibits (...) serological features that are distinct from those of antithyroid agent-induced vasculitis syndrome. The absence of autoantibodies, especially anti-neutrophil cytoplasmic antibodies, may help characterize and diagnose antithyroid arthritis syndrome. Furthermore, physicians' awareness of this syndrome is essential for its diagnosis in clinical practice.

Full Text available with Trip Pro

2016 Internal Medicine

55. Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective Trial. (PubMed)

Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate-Severe Graves' Orbitopathy: A Randomized Prospective Trial. The optimal therapeutic choice for Graves' hyperthyroidism in the presence of moderate-severe Graves' orbitopathy (GO) remains controversial.We aimed to compare GO course in patients with moderate-severe GO treated with early total thyroidectomy (TTx) versus antithyroid drug (ATD) regimens, in a prospective, randomized manner.Forty-two patients

Full Text available with Trip Pro

2016 European thyroid journal Controlled trial quality: uncertain

56. Genetic Study of Antithyroid Drugs Associated Agranulocytosis

Genetic Study of Antithyroid Drugs Associated Agranulocytosis Genetic Study of Antithyroid Drugs Associated Agranulocytosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Genetic Study of Antithyroid Drugs (...) Hospital Information provided by (Responsible Party): National Taiwan University Hospital Study Details Study Description Go to Brief Summary: Thionamides, the antithyroid drugs, have been widely used to treat hyperthyroidism1. Side effects are found in 1% - 5% of the patients1. One of the most serious side effect is agranulocytosis, which occurs in 0.1% - 0.3 % of the patients1. This might lead to severe infection and sometimes mortality. The underlying mechanism is unclear. An immune phenomenon may

2013 Clinical Trials

57. Antithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations (PubMed)

Antithyroid drugs induced agranulocytosis and multiple myeloma: case report and general considerations Antithyroid drugs as thionamides are largely used in the treatment of the thyrotoxicosis. Side effects were reported in less than 10% of the cases, especially hematological, hepatic or skin allergies. One of the most severe manifestations is agranulocytosis, probably based on an immune mechanism that is exacerbated by the presence of the thyroid autoimmune disease itself. If the presence (...) of the severe leucopenia is actually an epiphenomenon of a preexisting hematological disturbance as multiple myeloma is debated. The myeloma may also be correlated with an autoimmune predisposition. We present the case of a 56 years old female patient diagnosed with Graves' disease, who developed agranulocytosis after 8 months of therapy with thiamazole. Two months after antithyroid drug's withdrawal, the granulocytes number increased and she received therapy with radioiodine. Two years later she came back

Full Text available with Trip Pro

2013 Journal of medicine and life

58. Antithyroid Drug

Antithyroid Drug Antithyroid Drug Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Antithyroid Drug Antithyroid Drug Aka: Antithyroid (...) PTU dose down after 4-6 weeks Goal: maintain normal function Dose: reduce to 50-100 mg per day Dosing: Other : 1 gram load, then 300 mg PO q6 hours : 50-100 mg PO qd V. Adverse effects (3 per 1000 patients) (more common with PTU) Risk increases over age 40 years Occurs in 0.17% of those on Methimazole Presentation: Infection (e.g. ) Course Resolves within 2-3 weeks after drug stopped Severe, refractory course may occur Contraindication to further Antithyroid Drugs Cholestatic Occurs more commonly

2015 FP Notebook

59. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. (PubMed)

Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Use of the antithyroid drugs (ATDs) thiamazole (MMI) and propylthiouracil (PTU) is associated with a high frequency of side effects. When patients experience side effects with one (the 1st) ATD, it is usually discontinued and another is administered (the 2nd ATD). We investigated side effects associated with the 1st and 2nd ATDs.Four hundred forty-nine patients with untreated Graves' disease (GD) were randomly

2012 Clinical endocrinology Controlled trial quality: uncertain

60. Antithyroid Drug Treatment of Thyrotoxicosis in Young People

Antithyroid Drug Treatment of Thyrotoxicosis in Young People Antithyroid Drug Treatment of Thyrotoxicosis in Young People - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Antithyroid Drug Treatment (...) Hormones Propylthiouracil Carbimazole Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antimetabolites Molecular Mechanisms of Pharmacological Action Antithyroid Agents Hormone Antagonists

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>